2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Saturday, December 12, 2026
02:00 p.m. - 03:30 p.m.
MCCNO - 252-254
Access, Representation, Population Health, Treatment Considerations, Biological Therapies, Transplantation, Clinical Practice (Health Services and Quality), Health Economics, Practice Models, Quality of Care, Value, Diseases, Hemoglobinopathies, Sickle Cell Disease, Thalassemia, Research, Clinical Research, Health Outcomes Research, Patient-Reported Outcomes, Real-World Evidence, Study Population, Human, Adult, Pediatric, Pregnant, Young Adult
PAPER

304 Prevalence and multidimensional cognitive profiles in adults with sickle cell disease: A systematic screening study in an unselected cohort

Justine Roy, MD, MSc, Laurence Tavenas, MD2, Valérie Fraïle, PhD3, Christian Stapf, MD4, Olena Bereznyakova, MD5, Gregory Jacquin, MD6, Jonathan St-Onge, MD7, Sara-Maude Desforges, MD8, Maryline Couette, Dr, PhD9, Stephanie Forte, MD, MSc10
1 Centre hospitalier de l'Université de Montréal, Montreal, Quebec, Canada, University of Montreal, Montreal, Quebec, Canada
2 Centre hospitalier de l'Université de Montréal, Montreal, Quebec, Canada, University of Montreal, Montreal, Quebec, Canada
3 Centre hospitalier de l'Université de Montréal, Montreal, Quebec, Canada
4 Centre hospitalier de l'Université de Montréal, Montreal, Quebec, Canada
5 Centre hospitalier de l'Université de Montréal, Montreal, Quebec, Canada
6 Centre hospitalier de l'Université de Montréal, Montreal, Quebec, Canada
7 Centre hospitalier de l'Université de Montréal, Montreal, Quebec, Canada, University of Montreal, Montreal, Quebec, Canada
8 Centre hospitalier de l'Université de Montréal, Montreal, Quebec, Canada, University of Montreal, Montreal, Quebec, Canada
9 Brain Institute (ICM), Paris, France, Hôpital Saint-Antoine, Paris, France
10 Centre hospitalier de l'Université de Montréal, Montreal, Quebec, Canada, CHUM Research Center (CRCHUM), Montreal, Quebec, Canada

Background: Neurocognitive impairment is an increasingly recognized complication of sickle cell disease (SCD) in adults. The prevalence and spectrum of cognitive abnormalities remain poorly defined, as prior studies mainly included neurologically referred cohorts. Cognitive profiles identified by brief screening tools in routine care also remain poorly characterized. We aimed to determine the prevalence, clinical correlates, and cognitive screening profiles of neurocognitive abnormalities in adults with SCD undergoing routine surveillance.

Methods: We conducted a retrospective observational study of unselected adults with SCD screened at a specialized clinic between 2021 and 2026. All participants underwent systematic screening with the Montreal Cognitive Assessment (MoCA) and the Rowland Universal Dementia Assessment Scale (RUDAS), regardless of symptoms or imaging findings. All participants underwent brain MRI. A vascular neurologist integrated cognitive screening results with clinical and functional assessment to classify participants as having: 1) preserved cognition; 2) a study-defined attentional and/or psychomotor phenotype without established NCD; or 3) minor or 4) major NCD according to VASCOG criteria. Clinical, laboratory and imaging characteristics, including parenchymal brain MRI abnormalities (silent cerebral infarcts, overt stroke, and cerebral microangiopathy/white matter anomalies), were compared across groups. Multivariable ordinal regression was used to identify factors associated with cognitive impairment severity.

Results: A total of 331 adults with SCD were included (mean age 33.5±11.8 years; 41.7% male). No patients were excluded because of missing data. Among the patients, 228 (68.9%) had no cognitive deficits, 68 (20.5%) had attentional deficits and/or psychomotor slowing, 19 (5.7%) had minor neurocognitive disorder, and 16 (4.8%) had major neurocognitive disorder. Greater cognitive severity was associated with older age (p<0.001), lower education (p=0.035), lower RUDAS and MoCA screening scores (p<0.001 for both), and higher parenchymal brain MRI abnormalities (p=0.015). Patients with major neurocognitive disorder had the highest prevalence of chronic pain (50.0% vs 15.6% in the remaining groups; Fisher's exact p=0.002). They were also the least likely to have received specialized pediatric follow-up (12.5% vs 44.3%, 47.1%, and 26.3% in the other cognitive groups; p=0.032).

MoCA scores differed significantly between all cognitive groups (all p<0.001) except between patients with attentional deficits and/or psychomotor slowing and those with minor neurocognitive disorder (post hoc p=1.00). RUDAS scores were significantly lower in participants with minor or major neurocognitive disorder than in those with preserved cognition (all p<0.001) but did not differ between the attentional deficits/psychomotor slowing phenotype and preserved cognition (p=0.055) or minor neurocognitive disorder (p=0.150).

In multivariable ordinal regression analysis, older age (OR 1.06 per year, 95% CI 1.04–1.09; p<0.001) and parenchymal brain MRI abnormalities (OR 1.75, 95% CI 1.05–2.90; p=0.030) remained independently associated with greater impairment severity. Higher educational attainment was associated with a nonsignificant trend toward lower impairment severity (OR 0.91 per year of education, 95% CI 0.82–1.01; p=0.080). No laboratory characteristics such as hemoglobin, creatinine, reticulocyte count, and LDH differed significantly between groups in this model.

Conclusion: Systematic neurocognitive assessment identified attentional deficits and/or psychomotor slowing without established neurocognitive disorder (NCD) in 20.5% of adults with SCD, while an additional 10.6% met criteria for minor or major NCD, including young individuals without prior neurological referral. Increasing age and parenchymal brain MRI abnormalities were the strongest independent predictors of impairment severity, supporting surveillance stratification. The overlap between attentional deficits/psychomotor slowing and minor NCD suggests that these early manifestations are difficult to distinguish using current screening tools. Alternatively, they may represent a distinct phenotype. These findings may reflect a continuum of early cognitive dysfunction or limitations of current frameworks and screening tools, highlighting the need for age-appropriate, SCD-specific neurocognitive criteria and thresholds.

Justine Roy, MD, MSc: No relevant conflicts of interest to declare.